The US Food and Drug
Administration (FDA) has approved two single-pill combination medications,
Diovan HCT(R) (valsartan and hydrochlorothiazide) and Exforge(R)
(amlodipine and valsartan), as initial or ‘first-line’ therapies in
patients likely to need multiple drugs to achieve their blood pressure

Science has found many links between depression and other serious medical illnesses, such as cancer, stroke, diabetes, and heart disease. For example, people who develop depression following a heart attack (myocardial infarction) or chest pain (angina) have an elevated risk of cardiac death or hospital readmission over the following year. In

UCSF researchers investigating the appropriate use of procedures to open narrowed coronary arteries — such as angioplasty and stenting — found that less than half of Medicare patients had documented noninvasive stress testing prior to elective percutaneous coronary intervention, or PCI, the clinical name for such procedures.
The team analyzed a 20 percent random sample of […]

A landmark study indicating that angioplasty may not be cost effective for some stable heart disease patients and research indicating individualized consent forms may help patients make better decisions are among topics reported in the debut issue of Circulation: Cardiovascular

Your blood pressure changes from hour to hour, sometimes minute to minute. Standing up from a chair, watching an exciting show, eating a meal, or being stressed-perhaps because of a visit to the doctor-all influence your blood pressure. Blood

African-American patients with acute myocardial infarction (MI) and previously treated depression that persists at their MI hospitalization have an increased risk of post-MI death, according to Emory researcher Susmita Parashar, MD, MPH.
Parashar, a member of the cardiology division, Emory University School of Medicine, presented

Soliris® (eculizumab), a terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), reduced blood measures associated with undiagnosed dangerous blood clots and inflammation in patients with PNH, providing support of possible anti-thrombotic properties of Soliris in patients with PNH.
A separate study found that Soliris reduced indicators